Pharmesis International (SGX:BFK) PEG Ratio: N/A (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:BFK Pharmesis International Ltd SGX:BFK
31 GF Score
Price S$0.11
GF Value S$0.09
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Pharmesis International PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Pharmesis International's PE Ratio without NRI is 0.00. Pharmesis International's 5-Year EBITDA growth rate is 0.00%. Therefore, Pharmesis International's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Pharmesis International's PEG Ratio or its related term are showing as below:



SGX:BFK's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.8
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Pharmesis International  (SGX:BFK) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Pharmesis International PEG Ratio Related Terms


Pharmesis International PEG Ratio Historical Data

* Premium members only.

The historical data trend for Pharmesis International's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmesis International PEG Ratio Chart

Pharmesis International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharmesis International Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SGX:BFK vs ZTS, UTHR, VTRS: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmesis International's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmesis International PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmesis International's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Pharmesis International's PEG Ratio falls into.


SGX:BFK
31GF Score
Pharmesis International Ltd SGX:BFK
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmesis International PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Pharmesis International's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Pharmesis International (SGX:BFK) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmesis International stock appears to be overvalued. The current stock price of S$0.11 is trading 18.9% above its estimated GF Value™ of S$0.09. GuruFocus considers Pharmesis International to be Modestly Overvalued.

Key valuation signals for SGX:BFK:

  • PEG Ratio: N/A
  • GF Value™: S$0.09 vs. price of S$0.11 (18.9% above fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmesis International Business Description

Address 5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
31GF Score

Get the complete analysis for SGX:BFK

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.11
Price
S$0.09
GF Value